The group makes money by owning strong positions in four chronic-care niches and turning repeatDemandinto rising margins. In 2025 it generatedRevenueof $2,439m, nearly all from recurring, chronic-condition products. The model is simple: win the patient early, often in hospital, then keep supplying them at …
Oxford Nanopore Technologies plc — LSE:ONT closed 1.69% lower on 23 September 2026, with the shares at 175.00p after a decline of 3.00p on the day.
Oxford Biomedica plc — LSE:OXB closed 0.20% higher on 23 September 2026, with the shares at 494.00p after a gain of 1.00p on the day.
Oxford Nanopore closed up 5.8p, or about 3.37%, at 178p on Tuesday, against a previous close of 172.2p. Earlier reports during the session put the gain at around 2.8%. The move reversed a small dip on Monday, when the shares slipped from 174.4p, and …
Genus now goes beyond simply picking the best animals. It uses genomic selection, semen sexing and gene editing. Its PRRS-resistant pig (PRP) is edited to resist porcine reproductive and respiratory syndrome, one of the most costly diseases in pig farming. The US Food and …
The reinvention has three strands. First, a sales mix tilted towards higher-growth specialty products. Second, more aggressive deal-making, capped in June 2026 by the roughly $10.6bn agreedTakeoverof US biotech Nuvalent, GSK's largest deal in more than a decade. Third, a new three-year "Accelerate Growth" …
That development arrives alongside a strong set of full-year numbers. In preliminary results published on 10 September 2026 for the year to 30 June 2026, adjusted profit before tax rose 35% to £100.2m and adjustedBasic Earnings Per Sharealso climbed 35% to 110.3p, even thoughRevenuedipped …
The operational picture in 2026 has been steady. Interim results published on 6 August 2026 showed first-halfRevenueup 4% to $1,728m and core operating profit up 9% to $405m. Management reiterated full-year guidance for revenue growth of 2–4% at constant currency and core operating profit …
The trading picture has held up through the upheaval. In an update on 23 July 2026, CVS reported unauditedRevenueup 5.9% to £712.8m for the year to 30 June 2026, with like-for-like sales growth of 2.1%, against 0.2% a year earlier, despite a softer UK …
On 22 September 2026, Smith & Nephew (LSE:SN.), a FTSE 100 constituent, said the US Food and Drug Administration had granted 510(k) clearance for its LANDMARK Total Knee System. It also announced the first surgical cases using the implant. The launch is the company's …